| Distribution | Full List | Categories |
| by Country | by Vaccine |
| PEOPLE VACCINATED | LAST 7 DAYS | |||||
| countries over 1M population |
1st dose |
last dose |
1st dose |
last dose |
any dose |
|
| United Arab Emirates |
100.0% 9,890,572 |
92.9% 9,188,341 |
0.1% | 0.5% |
1.9% 189k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V | ||||||
| Portugal |
93.4% 9,529,327 |
89.9% 9,163,934 |
2.1% | 0.3% |
4.7% 480k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Cuba |
92.8% 10,517,029 |
86.2% 9,761,822 |
0.4% | 0.5% |
10.7% 1,210k |
|
| Abdala, Soberana02 | ||||||
| Chile |
91.4% 17,473,211 |
87.7% 16,763,095 |
0.4% | 0.6% |
2.8% 545k |
|
| CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| China |
87.8% 1,263,691,000 |
84.8% 1,220,584,000 |
0.1% | 0.3% | ||
| CanSino, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, ZF2001 | ||||||
| South Korea |
86.8% 44,484,806 |
84.8% 43,504,026 |
0.2% | 0.9% |
5.7% 2,894k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Argentina |
86.3% 38,988,156 |
74.7% 33,756,176 |
0.8% | 1.1% |
6.1% 2,748k |
|
| CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Spain |
86.2% 40,317,861 |
81.6% 38,144,506 |
0.8% | 0.2% |
3.5% 1,661k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Cambodia |
85.5% 14,296,897 |
81.9% 13,699,943 |
0.1% | 0.1% |
3.3% 548k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac | ||||||
| Canada |
84.9% 32,050,582 |
78.6% 29,651,921 |
0.4% | 0.4% |
6.7% 2,523k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Denmark |
83.4% 4,833,489 |
80.8% 4,677,546 |
0.2% | 1.1% |
5.2% 299k |
|
| Johnson&Johnson, Moderna, Pfizer/BioNTech | ||||||
| New Zealand |
82.7% 3,988,847 |
80.8% 3,895,725 |
0.2% | 0.5% |
5.9% 286k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Singapore |
82.4% 4,821,829 |
80.8% 4,726,199 |
0.8% | 0.2% |
6.0% 352k |
|
| Moderna, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Australia |
82.0% 20,905,692 |
78.5% 20,015,852 |
1.5% | 0.5% |
7.6% 1,933k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Ecuador |
82.0% 14,460,922 |
73.8% 13,027,708 |
0.9% | 1.2% |
4.3% 758k |
|
| CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Qatar |
81.9% 2,360,308 |
77.0% 2,218,292 |
4.5% 130k |
|||
| Moderna, Pfizer/BioNTech | ||||||
| France |
81.7% 53,352,671 |
77.5% 50,572,279 |
0.3% | 0.9% |
6.1% 4,002k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Italy |
81.7% 49,390,628 |
75.0% 45,326,327 |
0.9% | 0.5% |
7.5% 4,544k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Uruguay |
80.8% 2,806,764 |
77.3% 2,684,053 |
1.0% | 0.2% |
4.2% 146k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Vietnam |
80.7% 78,563,059 |
70.3% 68,435,813 |
0.4% |
8.3% 8,052k |
||
| Abdala, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Malaysia |
80.5% 26,044,184 |
79.3% 25,675,722 |
0.0% | 0.1% |
4.7% 1,521k |
|
| CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Ireland |
80.3% 3,966,572 |
78.0% 3,852,969 |
1.1% | 0.1% |
3.8% 185k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Japan |
80.0% 101,172,002 |
78.7% 99,495,264 |
0.3% | 0.3% |
0.8% 958k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Norway |
79.3% 4,298,860 |
72.9% 3,954,753 |
0.1% | 0.3% |
6.6% 357k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Taiwan |
79.1% 18,846,087 |
70.8% 16,852,665 |
0.3% | 1.3% |
1.6% 392k |
|
| Medigen, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Finland |
78.8% 4,365,075 |
75.2% 4,166,256 |
0.1% | 0.2% |
5.4% 299k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Brazil |
78.5% 166,909,237 |
68.4% 145,459,361 |
0.1% | 0.5% |
2.2% 4,658k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Kuwait |
78.4% 3,348,999 |
75.7% 3,234,464 |
0.2% | 0.2% |
2.1% 91k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Netherlands |
77.9% 13,342,689 |
71.7% 12,282,320 |
0.0% | 0.1% |
3.5% 593k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Costa Rica |
77.8% 3,965,650 |
70.5% 3,590,471 |
0.2% | 0.9% |
2.7% 137k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Belgium |
77.4% 8,965,642 |
76.2% 8,829,579 |
0.3% | 0.1% |
6.6% 763k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Sweden |
77.2% 7,791,147 |
73.9% 7,468,000 |
0.2% | 0.4% |
3.1% 314k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Israel |
77.1% 6,669,355 |
69.5% 6,015,063 |
0.5% | 0.6% |
5.1% 445k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Colombia |
76.8% 39,093,566 |
58.4% 29,697,446 |
0.9% | 1.6% |
3.3% 1,702k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| United Kingdom |
76.7% 52,071,960 |
70.5% 47,866,176 |
0.2% | 0.3% |
2.0% 1,390k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Sri Lanka |
75.6% 16,189,227 |
64.8% 13,869,020 |
0.9% | 0.1% |
2.6% 562k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Nicaragua |
75.4% 4,995,870 |
47.4% 3,140,060 |
0.9% | 1.8% |
2.7% 175k |
|
| Abdala, Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Soberana02, Sputnik Light, Sputnik V | ||||||
| United States |
75.1% 248,707,432 |
62.7% 207,371,017 |
0.4% | 0.2% |
1.4% 4,663k |
|
| Johnson&Johnson, Moderna, Pfizer/BioNTech | ||||||
| Mauritius |
75.0% 954,272 |
72.0% 915,442 |
0.3% | 0.2% |
1.6% 21k |
|
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Peru |
74.9% 24,707,462 |
67.0% 22,088,234 |
0.4% | 1.1% |
4.8% 1,596k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Germany |
74.4% 62,350,942 |
72.1% 60,382,284 |
0.4% | 0.8% |
5.1% 4,298k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Austria |
74.2% 6,687,252 |
73.8% 6,648,160 |
0.4% | 0.8% |
3.6% 325k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Thailand |
73.1% 51,032,649 |
65.1% 45,423,045 |
0.7% | 1.4% |
3.7% 2,564k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Greece |
73.1% 7,618,467 |
68.8% 7,169,425 |
0.8% | 0.8% |
5.2% 540k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Saudi Arabia |
72.4% 25,191,155 |
67.4% 23,450,290 |
0.2% | 0.4% |
3.8% 1,334k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Iran |
71.8% 60,289,939 |
63.2% 53,064,275 |
0.3% | 0.8% |
4.3% 3,637k |
|
| COVIran Barekat, Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing, Soberana02, Sputnik V | ||||||
| Panama |
71.1% 3,068,161 |
57.6% 2,485,530 |
0.7% | 0.2% |
4.2% 179k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Bahrain |
71.1% 1,209,714 |
69.8% 1,187,632 |
0.2% | 0.3% |
2.0% 34k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Lithuania |
71.1% 1,934,638 |
67.9% 1,849,137 |
0.3% | 0.3% |
3.0% 80k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Latvia |
70.3% 1,326,942 |
67.7% 1,277,203 |
0.3% | 0.3% |
3.3% 62k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Switzerland |
69.6% 6,019,032 |
67.9% 5,876,285 |
0.3% | 0.3% |
5.3% 458k |
|
| Moderna, Pfizer/BioNTech | ||||||
| El Salvador |
69.2% 4,486,892 |
64.2% 4,164,802 |
0.1% | 0.2% |
0.8% 52k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Mongolia |
69.2% 2,267,546 |
66.1% 2,167,267 |
0.0% | 0.0% |
0.8% 28k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Hong Kong |
68.3% 5,123,177 |
63.0% 4,721,481 |
1.6% | 0.3% |
3.7% 281k |
|
| Pfizer/BioNTech, Sinovac | ||||||
| Turkey |
67.9% 57,245,214 |
61.8% 52,112,351 |
0.2% | 0.3% |
3.6% 3,074k |
|
| Pfizer/BioNTech, Sinovac | ||||||
| Morocco |
66.9% 24,701,243 |
62.5% 23,088,979 |
0.1% | 0.1% |
1.2% 452k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| India |
65.8% 908,005,349 |
47.4% 653,514,044 |
2.0% | 1.9% |
4.2% 57,631k |
|
| Covaxin, Oxford/AstraZeneca, Sputnik V | ||||||
| Hungary |
65.2% 6,294,707 |
62.5% 6,033,675 |
0.3% | 0.5% |
1.9% 179k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Venezuela |
64.7% 18,393,519 |
40.8% 11,608,305 |
2.7% | 2.4% |
5.1% 1,453k |
|
| Abdala, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Czechia |
64.3% 6,886,289 |
62.8% 6,729,799 |
0.3% | 0.3% |
4.4% 470k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Dominican Republic |
64.2% 6,966,253 |
52.9% 5,740,955 |
0.1% | 0.2% |
1.1% 124k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Indonesia |
64.2% 175,645,471 |
14.9% 40,867,993 |
2.2% |
3.3% 8,920k |
||
| Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Estonia |
64.0% 849,567 |
62.1% 823,673 |
0.2% | 0.2% |
0.4% 5k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Mexico |
63.5% 81,916,351 |
56.5% 72,846,741 |
0.0% | 0.1% |
0.3% 379k |
|
| CanSino, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Oman |
61.1% 3,121,894 |
56.8% 2,902,254 |
0.0% | 0.2% |
1.4% 72k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Slovenia |
60.5% 1,257,555 |
57.9% 1,203,464 |
0.2% | 0.4% |
3.0% 62k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Rwanda |
60.2% 7,804,111 |
43.8% 5,680,013 |
0.8% | 1.1% |
3.2% 409k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Tunisia |
59.4% 7,018,208 |
51.4% 6,078,905 |
0.4% | 0.5% |
1.1% 131k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Poland |
58.2% 22,038,075 |
56.7% 21,439,572 |
0.5% | 0.6% |
3.6% 1,357k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Uzbekistan |
56.8% 19,008,051 |
17.6% 5,882,086 |
0.4% |
2.6% 876k |
||
| Moderna, Oxford/AstraZeneca, Sputnik V, ZF2001 | ||||||
| Croatia |
55.5% 2,279,054 |
53.1% 2,178,632 |
0.3% | 0.5% |
3.2% 130k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Bolivia |
54.8% 6,395,424 |
42.0% 4,903,386 |
2.6% | 1.2% |
4.7% 552k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Belarus |
52.8% 4,991,491 |
39.3% 3,718,448 |
0.9% | 1.6% |
2.8% 262k |
|
| Sinopharm/Beijing, Sputnik V | ||||||
| Trinidad and Tobago |
52.0% 727,066 |
48.5% 679,282 |
0.5% | 0.4% |
1.5% 21k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Bangladesh |
51.8% 85,287,956 |
34.1% 56,191,252 |
2.2% | 1.8% |
4.0% 6,639k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Laos |
51.5% 3,744,740 |
42.6% 3,099,003 |
1.5% | 1.6% |
1.8% 130k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V | ||||||
| Azerbaijan |
51.3% 5,198,072 |
46.5% 4,712,091 |
0.2% | 0.2% |
1.7% 177k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Russia |
51.2% 74,754,560 |
47.0% 68,617,125 |
0.4% | 1.0% |
1.8% 2,577k |
|
| EpiVacCorona, Sputnik V | ||||||
| Philippines |
51.2% 56,110,301 |
49.7% 54,423,286 |
2.5% |
4.9% 5,429k |
||
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Honduras |
50.8% 5,034,950 |
44.2% 4,381,943 |
0.2% | 0.3% |
0.5% 51k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V | ||||||
| Slovakia |
50.6% 2,762,262 |
47.9% 2,616,764 |
0.3% |
3.2% 172k |
||
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V | ||||||
| Timor |
50.5% 665,588 |
41.3% 544,482 |
0.1% | 0.4% |
0.5% 7k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Nepal |
50.0% 14,564,533 |
36.8% 10,710,721 |
3.7% | 1.6% |
5.3% 1,534k |
|
| Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Botswana |
49.8% 1,171,577 |
44.2% 1,039,113 |
0.1% | 0.2% |
0.3% 7k |
|
| Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Paraguay |
49.2% 3,510,071 |
42.7% 3,044,839 |
0.3% | 0.6% |
2.7% 193k |
|
| Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Serbia |
48.8% 3,321,143 |
47.5% 3,229,603 |
0.0% | 0.1% |
0.3% 18k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Kazakhstan |
48.2% 9,053,943 |
45.8% 8,609,356 |
0.2% | 0.2% |
0.4% 68k |
|
| QazVac, Sinopharm/Beijing, Sputnik V | ||||||
| Kosovo |
46.9% 906,354 |
41.0% 791,547 |
0.7% | 0.4% |
1.1% 21k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Pakistan |
45.9% 101,457,925 |
34.7% 76,649,649 |
0.9% | 1.3% |
2.1% 4,721k |
|
| CanSino, Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Jordan |
42.5% 4,331,942 |
38.6% 3,933,851 |
0.4% | 0.5% |
0.9% 90k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Albania |
41.1% 1,183,130 |
37.1% 1,067,328 |
1.0% | 0.6% |
2.2% 63k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Palestine |
40.5% 2,066,723 |
29.7% 1,515,699 |
0.3% | 0.7% |
1.3% 67k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V | ||||||
| North Macedonia |
40.5% 842,871 |
39.2% 816,777 |
0.1% | 0.2% |
0.7% 14k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Tajikistan |
40.3% 3,844,805 |
32.0% 3,048,294 |
1.4% | 1.6% |
3.0% 288k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Myanmar |
38.3% 20,816,441 |
28.6% 15,571,917 |
1.2% | 1.6% |
2.8% 1,510k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Guatemala |
37.5% 6,708,674 |
27.8% 4,973,675 |
0.6% | 0.9% |
3.7% 668k |
|
| Moderna, Oxford/AstraZeneca | ||||||
| Georgia |
35.6% 1,418,512 |
29.9% 1,191,003 |
0.9% | 0.6% |
1.5% 58k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Egypt |
35.1% 35,914,913 |
23.0% 23,557,717 |
1.3% | 1.3% |
2.7% 2,808k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Lebanon |
35.1% 2,394,811 |
28.0% 1,913,395 |
0.8% | 0.7% |
2.0% 135k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Ukraine |
34.3% 14,985,041 |
32.7% 14,277,366 |
0.4% | 0.7% |
1.1% 467k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| South Africa |
32.6% 19,318,516 |
27.4% 16,231,689 |
0.4% | 0.4% |
0.6% 368k |
|
| Johnson&Johnson, Pfizer/BioNTech | ||||||
| Armenia |
32.2% 952,813 |
25.0% 740,489 |
0.3% | 0.9% |
1.2% 34k |
|
| Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Mozambique |
31.7% 9,921,960 |
24.9% 7,788,546 |
2.2% | 2.9% |
5.2% 1,611k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Mauritania |
31.2% 1,450,549 |
20.8% 968,079 |
6.1% | 4.3% |
10.5% 487k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Lesotho |
30.3% 648,817 |
29.9% 641,007 |
0.9% | 0.9% |
2.1% 46k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Romania |
28.5% 5,478,579 |
41.1% 7,912,048 |
0.2% |
0.8% 162k |
||
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Libya |
28.3% 1,946,622 |
13.5% 926,296 |
0.7% | 0.8% |
1.5% 105k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Zimbabwe |
28.3% 4,204,134 |
21.7% 3,228,685 |
0.3% | 0.3% |
0.6% 86k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| WORLD |
27.5% 2,147,483,647 |
27.5% 2,147,483,647 |
||||
| Bulgaria |
27.4% 1,904,143 |
28.2% 1,961,791 |
0.3% |
2.2% 153k |
||
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Bosnia and Herzegovina |
25.4% 833,233 |
22.0% 720,631 |
0.6% | 1.3% |
1.9% 61k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Angola |
25.2% 8,298,224 |
13.1% 4,308,880 |
1.3% | 0.8% |
2.4% 781k |
|
| Oxford/AstraZeneca | ||||||
| Jamaica |
24.6% 729,967 |
20.1% 594,224 |
0.3% | 0.4% |
0.8% 23k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Moldova |
23.5% 948,882 |
24.7% 997,886 |
0.2% |
1.0% 42k |
||
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Uganda |
22.8% 10,410,479 |
4.0% 1,809,627 |
1.5% | 0.3% |
1.8% 819k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Iraq |
21.9% 8,801,367 |
14.9% 6,007,244 |
0.4% | 0.4% |
0.9% 366k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Ghana |
21.5% 6,682,196 |
9.4% 2,918,596 |
1.0% | 0.7% |
2.1% 646k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Liberia |
20.1% 1,017,128 |
19.5% 984,421 |
2.0% | 2.0% |
2.3% 117k |
|
| Oxford/AstraZeneca | ||||||
| Guinea-Bissau |
19.9% 391,662 |
1.2% 23,534 |
0.0% | 0.0% |
0.0% 1k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Kyrgyzstan |
19.4% 1,266,300 |
15.6% 1,019,437 |
0.3% | 0.1% |
0.9% 57k |
|
| Sinopharm/Beijing, Sputnik V | ||||||
| Guinea |
18.8% 2,469,757 |
9.9% 1,293,373 |
0.3% | 0.1% |
0.4% 48k |
|
| Sputnik V | ||||||
| Cote d'Ivoire |
18.8% 4,950,775 |
8.2% 2,162,458 |
0.5% 139k |
|||
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Equatorial Guinea |
17.8% 249,840 |
14.5% 203,662 |
0.0% | 0.0% |
0.0% 0k |
|
| Sinopharm/Beijing | ||||||
| Gabon |
17.6% 392,898 |
7.8% 173,123 |
5.9% | 0.9% |
6.8% 151k |
|
| Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Togo |
16.9% 1,399,760 |
12.6% 1,040,674 |
0.1% | 0.2% |
0.4% 33k |
|
| Oxford/AstraZeneca | ||||||
| Algeria |
16.5% 7,221,896 |
13.1% 5,763,106 |
0.1% | 0.1% |
0.3% 133k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Namibia |
16.2% 411,163 |
13.7% 348,522 |
0.2% | 0.2% |
0.3% 8k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Benin |
15.0% 1,815,764 |
11.7% 1,421,442 |
1.0% | 0.8% |
1.0% 124k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Kenya |
13.5% 7,278,811 |
8.6% 4,644,213 |
0.6% | 0.6% |
1.0% 521k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Congo |
13.3% 734,721 |
10.2% 560,880 |
2.1% | 4.2% |
6.3% 347k |
|
| Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Syria |
13.0% 2,277,523 |
5.1% 883,478 |
3.3% | 0.3% |
3.6% 631k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V | ||||||
| Central African Republic |
11.5% 556,077 |
7.2% 346,270 |
1.2% |
1.2% 57k |
||
| Covaxin, Oxford/AstraZeneca | ||||||
| Afghanistan |
11.3% 4,405,897 |
9.8% 3,823,786 |
0.3% | 0.1% |
0.3% 115k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Gambia |
10.9% 263,056 |
10.3% 249,515 |
0.4% | 0.4% |
0.4% 9k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Sierra Leone |
9.4% 747,044 |
4.8% 385,232 |
0.1% | 0.1% |
0.1% 8k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Sudan |
9.2% 4,016,849 |
2.8% 1,234,386 |
2.8% |
4.5% 1,975k |
||
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Senegal |
8.2% 1,365,479 |
5.9% 994,643 |
0.1% | 0.3% |
0.4% 64k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Ethiopia |
8.1% 9,363,375 |
1.4% 1,595,221 |
0.0% | 0.0% |
0.0% 3k |
|
| Oxford/AstraZeneca | ||||||
| Malawi |
7.8% 1,498,902 |
3.9% 748,097 |
0.0% | 0.2% |
0.2% 34k |
|
| Johnson&Johnson, Oxford/AstraZeneca | ||||||
| Somalia |
7.6% 1,203,131 |
5.1% 810,010 |
0.8% | 0.4% |
0.9% 147k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac | ||||||
| Nigeria |
6.0% 12,391,384 |
2.4% 4,934,418 |
0.7% | 0.2% |
1.0% 2,032k |
|
| Oxford/AstraZeneca | ||||||
| Niger |
5.9% 1,424,863 |
4.2% 1,010,152 |
0.6% | 0.4% |
0.5% 131k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Burkina Faso |
5.3% 1,108,731 |
3.5% 725,952 |
0.3% | 0.2% |
0.4% 75k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Mali |
4.7% 942,853 |
2.7% 545,403 |
0.2% | 0.5% |
1.5% 301k |
|
| Oxford/AstraZeneca | ||||||
| Zambia |
4.4% 806,611 |
7.8% 1,434,882 |
0.8% |
1.1% 197k |
||
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Eswatini |
4.0% 345,602 |
3.7% 315,764 |
0.1% | 0.1% |
0.2% 14k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Tanzania |
3.5% 2,079,930 |
2.3% 1,359,225 |
0.3% | 0.2% |
0.4% 233k |
|
| Johnson&Johnson, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Papua New Guinea |
3.2% 288,879 |
2.5% 226,580 |
0.0% | 0.0% |
0.1% 5k |
|
| Oxford/AstraZeneca | ||||||
| Cameroon |
3.2% 837,860 |
2.5% 663,317 |
0.0% | 0.0% |
0.0% 3k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Madagascar |
3.0% 817,386 |
2.8% 767,113 |
0.2% | 0.2% |
0.2% 54k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| South Sudan |
2.2% 245,004 |
1.8% 199,740 |
0.0% | 0.1% |
0.1% 6k |
|
| Johnson&Johnson, Oxford/AstraZeneca | ||||||
| Yemen |
1.9% 556,652 |
1.2% 366,587 |
0.0% | 0.0% |
0.1% 17k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinovac | ||||||
| Chad |
1.7% 285,922 |
0.6% 95,267 |
0.0% |
0.0% 4k |
||
| Sinopharm/Beijing | ||||||
| Haiti |
1.1% 125,187 |
0.7% 75,028 |
0.0% | 0.0% |
0.0% 3k |
|
| Johnson&Johnson, Moderna | ||||||
| Democratic Republic of Congo |
0.3% 307,807 |
0.2% 160,327 |
0.0% | 0.0% |
0.1% 40k |
|
| Oxford/AstraZeneca | ||||||
| Burundi |
0.1% 5,474 |
0.0% 3,533 |
0.0% |
0.0% 1k |
||
| Sinopharm/Beijing | ||||||
| PEOPLE VACCINATED | LAST 7 DAYS | |||||
| countries below 1M population |
1st dose |
last dose |
1st dose |
last dose |
any dose |
|
| Gibraltar |
122.4% 41,232 |
119.1% 40,117 |
0.1% | 0.1% |
0.8% 0k |
|
| Pfizer/BioNTech | ||||||
| Malta |
103.3% 455,987 |
99.6% 439,956 |
1.4% | 0.6% |
9.2% 41k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Pitcairn |
100.0% 47 |
100.0% 47 |
||||
| Oxford/AstraZeneca | ||||||
| Brunei |
92.8% 406,153 |
91.8% 401,757 |
0.1% | 0.2% |
5.6% 25k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Cayman Islands |
89.7% 58,939 |
87.3% 57,377 |
0.2% | 0.3% |
2.4% 2k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Iceland |
87.6% 298,878 |
83.6% 285,125 |
2.9% | 0.2% |
6.2% 21k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Faeroe Islands |
85.0% 41,557 |
83.4% 40,739 |
0.1% | 0.2% |
4.4% 2k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Seychelles |
83.7% 82,348 |
79.6% 78,263 |
0.0% | 0.0% |
0.1% 0k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Isle of Man |
81.1% 68,978 |
77.4% 65,808 |
0.2% | 0.3% |
2.3% 2k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Jersey |
80.9% 81,762 |
76.7% 77,494 |
0.2% | 0.4% |
3.8% 4k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Guernsey |
80.8% 54,146 |
76.6% 51,351 |
31.6% | 56.3% |
3.0% 2k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Aruba |
79.8% 85,244 |
74.4% 79,391 |
0.2% | 0.2% |
0.4% 0k |
|
| Pfizer/BioNTech | ||||||
| Macao |
77.0% 499,836 |
72.4% 469,841 |
0.6% | 0.6% |
2.8% 18k |
|
| Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Bhutan |
76.7% 591,662 |
73.6% 567,977 |
0.1% | 0.2% |
0.3% 3k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Falkland Islands |
75.6% 2,632 |
51.0% 1,775 |
0.8% | 1.7% |
2.4% 0k |
|
| Oxford/AstraZeneca | ||||||
| Turks and Caicos Islands |
75.4% 29,210 |
70.1% 27,133 |
0.6% | 0.7% |
1.2% 0k |
|
| Pfizer/BioNTech | ||||||
| Luxembourg |
74.8% 468,360 |
6.1% 37,869 |
0.6% |
6.7% 42k |
||
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Bermuda |
74.7% 46,503 |
73.3% 45,670 |
0.1% | 0.2% |
1.5% 1k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Cyprus |
74.6% 653,003 |
70.8% 620,004 |
0.5% | 0.5% |
3.2% 28k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Niue |
74.3% 1,202 |
71.1% 1,150 |
17.9% |
18.2% 0k |
||
| Oxford/AstraZeneca | ||||||
| Fiji |
74.0% 663,598 |
68.2% 611,574 |
0.1% | 0.2% |
0.3% 2k |
|
| Oxford/AstraZeneca | ||||||
| Andorra |
73.9% 57,085 |
66.5% 51,392 |
0.3% | 0.5% |
1.0% 1k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Cook Islands |
73.7% 12,938 |
71.8% 12,610 |
0.3% | 0.3% |
0.6% 0k |
|
| Pfizer/BioNTech | ||||||
| Maldives |
73.4% 397,033 |
68.1% 368,351 |
0.0% | 0.1% |
0.4% 2k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Bonaire Sint Eustatius and Saba |
72.9% 19,109 |
63.8% 16,736 |
2.5% | 2.8% |
5.2% 1k |
|
| Moderna, Pfizer/BioNTech | ||||||
| San Marino |
71.9% 24,418 |
63.9% 21,690 |
0.1% |
2.7% 1k |
||
| Pfizer/BioNTech, Sputnik V | ||||||
| Nauru |
71.7% 7,764 |
68.0% 7,364 |
0.1% 0k |
|||
| Oxford/AstraZeneca | ||||||
| Samoa |
71.4% 141,724 |
61.8% 122,714 |
0.1% | 0.2% |
0.2% 0k |
|
| Oxford/AstraZeneca | ||||||
| Greenland |
71.3% 40,469 |
67.1% 38,089 |
0.0% | 0.1% |
0.1% 0k |
|
| Moderna | ||||||
| Tonga |
70.0% 73,956 |
60.7% 64,192 |
0.1% | 1.2% |
1.3% 1k |
|
| Oxford/AstraZeneca | ||||||
| Liechtenstein |
69.3% 26,428 |
67.7% 25,821 |
0.5% | 0.3% |
5.0% 2k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Monaco |
68.0% 26,672 |
59.4% 23,308 |
0.6% | 1.3% |
1.8% 1k |
|
| Pfizer/BioNTech | ||||||
| Anguilla |
67.7% 10,157 |
61.9% 9,282 |
0.1% | 0.1% |
1.0% 0k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| New Caledonia |
64.5% 184,033 |
61.4% 175,339 |
0.2% | 0.2% |
0.3% 1k |
|
| Pfizer/BioNTech | ||||||
| Curacao |
64.3% 105,544 |
59.2% 97,203 |
0.2% | 0.2% |
3.1% 5k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Antigua and Barbuda |
63.7% 62,361 |
60.3% 59,054 |
0.1% | 0.2% |
0.2% 0k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V | ||||||
| Sint Maarten (Dutch part) |
63.5% 27,247 |
59.0% 25,284 |
0.1% | 0.1% |
0.2% 0k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| French Polynesia |
61.9% 173,773 |
56.6% 159,100 |
0.6% |
0.6% 2k |
||
| Johnson&Johnson, Pfizer/BioNTech | ||||||
| British Virgin Islands |
61.3% 18,536 |
56.5% 17,072 |
0.2% | 0.1% |
0.3% 0k |
|
| Johnson&Johnson, Oxford/AstraZeneca | ||||||
| Kiribati |
59.6% 71,152 |
33.9% 40,534 |
3.9% | 2.0% |
6.0% 7k |
|
| Oxford/AstraZeneca | ||||||
| Belize |
58.0% 230,789 |
50.4% 200,254 |
0.1% | 0.1% |
0.6% 2k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Cape Verde |
57.8% 321,577 |
48.2% 268,046 |
0.8% | 1.4% |
3.6% 20k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Barbados |
54.7% 157,038 |
50.5% 145,217 |
0.3% | 0.5% |
0.8% 2k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Wallis and Futuna |
54.5% 6,130 |
54.4% 6,117 |
0.2% | 0.3% |
0.4% 0k |
|
| Moderna | ||||||
| Guyana |
52.3% 411,081 |
37.5% 295,325 |
0.2% | 0.4% |
0.8% 6k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Saint Kitts and Nevis |
52.2% 27,781 |
48.6% 25,830 |
0.2% | 0.2% |
1.1% 1k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Montenegro |
45.5% 285,593 |
43.9% 275,641 |
0.1% | 0.2% |
0.9% 6k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Suriname |
44.9% 263,209 |
39.3% 230,808 |
0.2% | 0.2% |
0.4% 2k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Dominica |
43.0% 30,953 |
39.8% 28,671 |
0.2% | 0.2% |
0.4% 0k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Bahamas |
40.4% 158,965 |
38.2% 150,372 |
0.2% | 0.2% |
1.2% 5k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Sao Tome and Principe |
39.4% 86,396 |
23.4% 51,216 |
0.6% | 2.5% |
3.0% 7k |
|
| Oxford/AstraZeneca | ||||||
| Comoros |
38.6% 335,408 |
28.3% 246,139 |
2.0% | 0.1% |
2.1% 18k |
|
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Grenada |
37.1% 41,767 |
32.0% 36,056 |
0.2% | 0.2% |
1.1% 1k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Vanuatu |
33.3% 102,308 |
16.4% 50,403 |
0.7% | 1.0% |
1.7% 5k |
|
| Oxford/AstraZeneca | ||||||
| Montserrat |
32.2% 1,612 |
29.6% 1,479 |
0.6% |
0.7% 0k |
||
| Oxford/AstraZeneca | ||||||
| Saint Lucia |
30.7% 56,339 |
27.4% 50,244 |
0.2% | 0.3% |
0.5% 1k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Saint Vincent and the Grenadines |
30.2% 33,494 |
23.6% 26,244 |
0.1% | 0.3% |
0.5% 1k |
|
| Oxford/AstraZeneca | ||||||
| Solomon Islands |
27.0% 185,485 |
8.8% 60,639 |
0.4% | 0.3% |
0.7% 5k |
|
| Oxford/AstraZeneca | ||||||
| Djibouti |
11.0% 108,945 |
10.0% 99,007 |
0.4% |
0.4% 4k |
||
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||